Clinical & Experimental Metastasis最新文献

{"title":"Cold atmospheric plasma-activated liquid inhibits peritoneal metastasis in drug-resistant ovarian cancer by targeting the epithelial-mesenchymal transition.","authors":"Jinren Liu, Xiangni Wang, Yixin Cui, Jiajia Lu, Zhirou He, Yulin Xu, Rongrong Li, Guimin Xu, Lingge Gao, Xiaolin Fan, Xili Wu, Xingmin Shi, Guanjun Zhang","doi":"10.1007/s10585-025-10367-w","DOIUrl":"https://doi.org/10.1007/s10585-025-10367-w","url":null,"abstract":"<p><p>Ovarian cancer remains a significant challenge in oncology due to its aggressive nature, late-stage diagnosis, and high rates of chemoresistance, particularly to platinum-based therapies like cisplatin. The epithelial-mesenchymal transition (EMT) is a key driver of ovarian cancer metastasis and drug resistance, highlighting the need for novel therapeutic strategies. Cold atmospheric plasma (CAP) and plasma-activated liquids (PAL), including plasma-activated medium (PAM) and saline (PAS), have emerged as promising anticancer agents, generating reactive oxygen and nitrogen species (RONS) that selectively target cancer cells. This study investigates the potential of PAL to inhibit the invasion and metastasis of cisplatin-resistant ovarian cancer cells and explores its synergistic effects with cisplatin. In vitro, PAM reduced proliferation, migration, and invasion of cisplatin-resistant ovarian cancer cells (A2780/DDP and SKOV3/DDP) while downregulating EMT-related proteins (N-cadherin, β-catenin, vimentin). H₂O₂ in PAM inhibit the PI3K/AKT/GSK3β pathway, promoting degradation of EMT regulators Snail, Slug, and β-catenin. Combining PAM with cisplatin enhanced therapeutic efficacy, reducing cell viability and metastatic potential. In vivo studies using an orthotopic mouse model further confirmed that PAS combined with low-dose cisplatin effectively suppressed tumor growth and metastasis with minimal side effects. These findings underscore the potential of PAL as an adjuvant therapy for cisplatin-resistant ovarian cancer, offering a novel approach to overcome drug resistance and inhibit metastasis. Future research should focus on optimizing treatment protocols and elucidating the molecular mechanisms underlying the synergistic effects of PAL and cisplatin.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 5","pages":"46"},"PeriodicalIF":3.2,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A CSF-1R inhibitor both prevents and treats triple-negative breast cancer brain metastases in hematogenous preclinical models.","authors":"Wei Zhang, Samiur Rahman, Alex M L Wu, Kristine Isanogle, Christina Robinson, Dinesh Kumar, Imran Khan, Debbie Wei, Alexandra S Zimmer, Takeo Fujii, Simone Difilippantonio, Stanley Lipkowitz, Patricia Steeg","doi":"10.1007/s10585-025-10366-x","DOIUrl":"10.1007/s10585-025-10366-x","url":null,"abstract":"","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 5","pages":"45"},"PeriodicalIF":3.2,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12321670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"G-protein coupled receptor 183 (GPR183) inhibits visceral metastasis of non-small cell lung cancer.","authors":"Lei Cheng, Shifang Li, Zhenwen Cui, Xuezhi Sun, Mengqi Gong, Yun Chen, Li Meng, Yiwei Liao","doi":"10.1007/s10585-025-10360-3","DOIUrl":"https://doi.org/10.1007/s10585-025-10360-3","url":null,"abstract":"<p><p>Brain metastasis is a serious complication of non-small cell lung cancer (NSCLC) that contributes to poor survival outcomes despite strides made in systemic treatment regimens. The G protein-coupled receptor GPR183 has been shown to regulate immune cell positioning; however, its role in lung cancer metastasis remains unclear. In this study, the specific effects of G-protein coupled receptor 183 (GPR183) on lung cancer cell phenotypes and a mouse brain and lung metastasis model were investigated in vitro and in vivo. Lung cancer cell lines with GPR183 overexpression were assessed for proliferation, apoptosis, and cell cycle progression through CCK-8, flow cytometry, and immunoblotting. Wound healing, Transwell migration, and invasion assays were used to investigate the metastatic potential of GPR183-overexpressing cells. Subcutaneous xenograft and lung metastasis models were used to examine the growth and metastasis ability of GPR183-overexpressing cells. Moreover, a brain metastasis model was established using A549 cells that were injected into mice, and tumor burden was monitored using bioluminescence imaging and IHC staining. The overexpression of GPR183 inhibited lung cancer cell proliferation, migration, and invasion by inhibiting ERK and Akt pathways. GPR183 also reduced angiogenesis in co-cultured endothelial cells and limited the invasion of lung cancer cells through the blood-brain barrier. In the mouse model, GPR183 significantly reduced metastatic burden. These findings suggest that GPR183 inhibits NSCLC visceral metastasis by modulating angiogenesis and metastatic pathways, presenting a potential therapeutic target for preventing brain metastasis in lung cancer patients.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 5","pages":"44"},"PeriodicalIF":3.2,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of concomitant use of proton pump inhibitors or cardiovascular medication on survival outcomes of patients with metastatic renal cell carcinoma treated with nivolumab.","authors":"Ondřej Fiala, Petr Hošek, Michaela Tkadlecová, Bohuslav Melichar, Anežka Zemánková, Jindřich Kopecký, Michal Vočka, Martin Matějů, Radka Lohynská, Dominika Šiková, Petr Stránský, Hana Študentová, Martina Spisarová, Hana Nováková, Peter Priester, Dominika Kryštofová, Lucie Grmelová, Tomáš Büchler, Alexandr Poprach","doi":"10.1007/s10585-025-10347-0","DOIUrl":"10.1007/s10585-025-10347-0","url":null,"abstract":"","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 5","pages":"43"},"PeriodicalIF":3.2,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415).","authors":"Farastuk Bozorgmehr, Inn Chung, Jürgen R Fischer, Marc Bischof, Akin Atmaca, Sophie Wetzel, Martin Faehling, Dirk Bottke, Martin Wermke, Esther G C Troost, Cornelia Kropf-Sanchen, Thomas Wiegel, Bernd Schmidt, Andrej Stupavsky, Walburga Engel-Riedel, Michaela Hammer-Hellmig, Niels Reinmuth, Farkhad Manapov, Christian Grohe, Robert Krempien, Christian Schumann, Florian Sterzing, Martin Reck, Florian Würschmidt, Jochen Fleckenstein, Alev Petroff, Sven Henschke, Rouven Behnisch, Jelena Cvetkovic, Lena Brückner, Constantin Schwab, Albrecht Stenzinger, Thorsten Götze, Christina Kopp, Helge Schröder, Jürgen Debus, Petros Christopoulos, Michael Thomas, Stefan Rieken","doi":"10.1007/s10585-025-10358-x","DOIUrl":"10.1007/s10585-025-10358-x","url":null,"abstract":"<p><p>Introduction of immune checkpoint inhibitors (ICI) has improved overall survival (OS) for advanced non-small cell lung cancer (NSCLC). However, responses differ greatly amongst patients. Additional radiotherapy (RT) may promote tumor-specific immunity and synergize with ICI to improve tumor control. The multicenter phase II FORCE trial evaluated safety and efficacy of nivolumab with additional palliative radiotherapy (5 × 4 Gy) as clinically indicated in pre-treated metastatic non-squamous NSCLC (group A, n = 41), including pretreated patients without an indication for radiotherapy in a parallel cohort as real-world controls (group B, n = 60). With an objective response rate (ORR) of 8.3% in group A (n = 41), the primary endpoint was not met (p = 0.991). ORR in group B (n = 60) was 23.8%. Patient characteristics indicated a significantly poorer baseline clinical condition for group A compared to B, including worse Eastern Cooperative Oncology Group (ECOG) performance status (PS, p = 0.020) and more metastatic sites (p = 0.009). Consequently, group A had shorter progression-free survival (median PFS, 1.9 versus 3.7 months, hazard ratio [HR] 1.69 [95% CI (1.10, 2.58)]) and OS (median 6.0 versus 12.6 months, HR 1.75 [95% CI (1.07, 2.84)]). In multivariable analyses for the intention-to-treat (ITT) population, ORR, PFS and OS were inversely associated with the patients' ECOG PS (ORR odds ratio [OR] 0.126, p = 0.004) and correlated positively with tumor PD-L1 expression (ORR OR 12.8, p = 0.022), but not with radiotherapy administration (p = 0.169-0.854). Adverse events were distributed equally in both groups. Addition of palliative radiotherapy to nivolumab was safe and feasible, but not associated with improved efficacy. Patients with an indication for palliative radiotherapy have an inherently worse prognosis which cannot be overcome by radiation-induced immunostimulation. Clinical features and PD-L1 expression influence clinical outcomes more than radiotherapy administration and should be considered when evaluating the effectiveness of immuno-/radiotherapy combinations.ClinicalTrials.gov identifier: NCT03044626.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 5","pages":"42"},"PeriodicalIF":4.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Loss of IL13RA2 promotes metastatic tumor growth in triple-negative breast cancer via increased AKT and NF-κB signaling.","authors":"Wendy E Bindeman, Kevin C Corn, Marjan Rafat, Barbara Fingleton","doi":"10.1007/s10585-025-10362-1","DOIUrl":"10.1007/s10585-025-10362-1","url":null,"abstract":"<p><p>Triple-negative breast cancer is associated with poor patient prognosis and high rates of distant metastasis. These patients are at elevated risk of brain metastasis, which remains a major therapeutic challenge. IL13RA2, a high-affinity receptor for IL13, is highly expressed in primary brain cancers, many extracranial solid tumors, and in lung- and brain-seeking metastatic variant cell lines. However, the relationship between IL13RA2 and patient prognosis is variable, and the biological function of this receptor in cancer remains controversial. We sought to define the role of IL13RA2 in triple-negative breast cancer growth and metastasis, with an emphasis on breast-to-brain metastasis. We generated IL13RA2-CRISPR knockout derivatives of the human brain-seeking breast cancer cell line MDA231BrM2, as well as murine 4T1 cells, and evaluated changes in gene expression, proliferation, survival, and metastatic growth in vivo. Both IL13RA2-deficient models demonstrate enhanced cell survival in vitro, as well as augmented metastatic tumor growth and worsened animal survival in intracardiac models of brain metastasis. Concordantly, elevated IL13RA2 mRNA expression is positively correlated with overall survival in patients with basal-like breast cancer. Mechanistically, IL13RA2-deficient cells exhibit increased AKT and NF-κB signaling. These cells are sensitive to inhibition of either pathway, but especially AKT, which may represent a clinically useful vulnerability for patients with IL13RA2-low tumors. Our data suggest that inhibition of IL13RA2, though promising in other tumor contexts, may be deleterious in metastatic triple-negative breast cancer.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 5","pages":"40"},"PeriodicalIF":4.2,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12263738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic significance of histopathological growth patterns in liver metastases undergoing surgery: a systematic review and meta-analysis.","authors":"Xiang-Yu Wang, Bo Zhang, Yin-Chen Gu, Mei Yang, Bao-Rui Tao, Rong-Quan Sun, Yi-Tong Li, Zhen-Mei Chen, Sen-Feng Ying, Chen-He Yi, Yan Geng, Rui Zhang, Jie Fan, Jin-Hong Chen","doi":"10.1007/s10585-025-10361-2","DOIUrl":"10.1007/s10585-025-10361-2","url":null,"abstract":"<p><p>Histopathological growth pattern (HGP) is emerging as a promising pathological biomarker in liver metastases, with potential associations to prognosis and response to antiangiogenic therapy. Nonetheless, its prognostic role requires further elucidation for substantial heterogeneity of previous studies. We searched PubMed, Web of Science, Embase and Cochrane Library for studies comparing the overall survival (OS) or disease-free survival (DFS) between different HGPs in liver metastases from various cancer types. Data were pooled using hazard ratios (HRs) along with 95% confidence intervals (CIs) according to fixed or random-effects models. Subgroup analysis was also performed to adjust critical confounders. In total, 36 studies were included in the final analysis. It was demonstrated that desmoplastic HGP (dHGP) was associated with favorable OS compared with non-dHGP (HR, 0.59; 95% CI 0.54-0.64), replacement HGP (rHGP, HR, 0.60; 95% CI 0.49-0.74) and pushing HGP (pHGP, HR, 0.63; 95% CI 0.43-0.92), respectively. Similarly, dHGP also demonstrated improved DFS compared with non-dHGP (HR, 0.58; 95% CI 0.52-0.65), rHGP (HR, 0.61; 95% CI 0.49-0.77) and pHGP (HR, 0.51; 95% CI 0.31-0.83), respectively. In subgroup analysis, dHGPs remains an independent prognostic factor regardless of critical confounders, such as the preoperative systemic therapy, cancer types and HGP categorization criteria. This study confirmed the prognostic role of HGPs in liver metastases receiving surgical resection. Clinically, adding HGPs in prognostic models may provide further optimization.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 5","pages":"41"},"PeriodicalIF":4.2,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The challenge of disappearing colorectal liver metastasis: balancing considerations between tumor biology and clinical consequence for liver surgery.","authors":"Daniel Ansari, Jenny Rystedt, Kjetil Søreide, Maria Lindberg, Roland Andersson","doi":"10.1007/s10585-025-10357-y","DOIUrl":"10.1007/s10585-025-10357-y","url":null,"abstract":"<p><p>The modern use of neoadjuvant and conversion systemic therapy in patients with colorectal cancer liver metastasis (CRLM) has improved resection rates and changed the borders between \"resectable\" and \"unresectable\" disease. Also, the use of preoperative systemic therapy has resulted in an increased frequency of disappearing liver metastasis (DLM). The optimal management of DLM is still controversial. In this review, we explore the current literature and highlight key findings relating to the tumor biology, diagnosis and treatment options of DLM. The definition of DLM should be based on hepatobiliary contrast MRI, which is the most sensitive preoperative imaging method. Patients with DLM are younger and more often have normalized their CEA-levels, and they have a better survival than those without DLM, likely reflecting favorable tumor biology and effective treatment response. Recent data indicate that molecular profiling (e.g. APC mutations) may predict CRLM at highest risk for vanishing after chemotherapy. However, just because the lesion has disappeared on imaging does not mean that there is a complete histopathological response. However a \"watch and wait\" strategy for patients with DLM is not associated with a reduced survival compared to resected DLM, but may be associated with a higher rate of recurrence often available for \"rescue therapy\", i.e. ablation or resection at the time when DLM recur and become visible. Furthermore, very few of \"blind resections\" of DLM contain viable tumor cells. International surveys among practicing hepatobiliary surgeons have revealed a widespread variation in the clinical management of DLM. In the future, biopsy and sequencing of metastases may be considered for therapeutic decision making in patients with CRLM considering the intricate tumor heterogeneity and clonal evolution of the disease.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 4","pages":"39"},"PeriodicalIF":3.2,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal cell carcinoma with metastasis to the pancreas: a model for oligometastasis, oligoprogression and metastatic organotropism.","authors":"Kjetil Søreide, Elen Martine Hauge, Maria Nyre Vigmostad","doi":"10.1007/s10585-025-10359-w","DOIUrl":"10.1007/s10585-025-10359-w","url":null,"abstract":"<p><p>Metastatic cancer has been considered uniformly fatal in the past with very poor outcomes for most cancer sites. However, novel systemic and targeted therapies have rendered unique responses with longer survival across several cancer types and metastatic sites. In addition, improved surgical experience and safety with good outcomes has made metastasectomy as an alternative curative-intent treatment across multiple organ sites. The pancreas is an uncommon site for metastasis, even if >30 different primary tumor entities have been described to metastasize to the pancreas. More than half of all resected metastasis in the pancreas are from renal cell carcinoma (RCC). RCC demonstrates a particular capacity to metastasize to nearly any site in the body-including uncommon sites like the tongue, salivary glands, spleen, testes, and pancreas-and, have remarkable plasticity and specific molecular trajectories with clinical implications. Cancer cells have a propensity to metastasize to specific organ sites, such as the lungs, liver or skeleton, called \"organotropism\" and the inherent tumor biology as well as the concept of 'oligometastatic' disease is still controversial and conflicting. Pancreatic metastasis has a very different biology from other RCC metastatic sites. Clinical observations suggest an indolent biology that warrants further investigation. Survival times are very long and approaching up to 10 years in recent series. In this paper we discuss the specific situation of pancreatic metastasis from RCC, the relation to oligometastasis and organotropism and how this can be viewed as a model to better understand cancer biology.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 4","pages":"38"},"PeriodicalIF":3.2,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD18 and CD36 expression in neutrophils from tumors and tumor-draining lymph nodes: implications for metastasis in oral squamous cell carcinoma.","authors":"Sandra Ekstedt, Eduardo I Cardenas, Krzysztof Piersiala, Vilma Liljeström, Marianne Petro, Monika Ezerskyte, Pedro Farrajota Neves da Silva, Susanna Kumlien Georén, Lars-Olaf Cardell","doi":"10.1007/s10585-025-10356-z","DOIUrl":"10.1007/s10585-025-10356-z","url":null,"abstract":"<p><strong>Background: </strong>Neutrophil infiltration in tumors and tumor-draining lymph nodes (TDLNs) influences oral squamous cell carcinoma (OSCC) progression and metastasis. Neutrophils can exhibit an immunosuppressive phenotype, with CD18 and CD36 potentially linked to this. This study characterizes CD18/CD36 expression on neutrophils from different OSCC microenvironments and their association with metastasis.</p><p><strong>Methods: </strong>We assessed CD18 and CD36 expression on neutrophils from OSCC tumors, TDLNs, and healthy lymph nodes using flow cytometry. We also examined whether co-culture with the CAL27 oral cancer cell line influenced CD18/CD36 expression in blood neutrophils from healthy donors.</p><p><strong>Results: </strong>Neutrophils from OSCC tumors and TDLNs exhibited higher CD18 expression than those from healthy lymph nodes, while CD36 was increased only in OSCC tumors. The highest CD18/CD36 expression was observed in metastasis. In vitro co-culture with CAL27 cells prolonged neutrophil survival and enhanced CD18 expression but had no impact on CD36 levels.</p><p><strong>Conclusion: </strong>Increased CD18/CD36 expression in OSCC neutrophils, particularly in metastasis, suggests their role in tumorigenesis. The elevated CD18 expression in TDLNs highlights enhanced neutrophil-lymphocyte interactions during cancer progression. Our in vitro findings underscore the ability of cancer cells to modulate neutrophil lifespan and phenotype, though this may not fully replicate the tumor microenvironment. This study provides insight into neutrophil contributions to OSCC progression and supports their potential as therapeutic targets.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 4","pages":"37"},"PeriodicalIF":3.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}